A specific small-molecule inhibitor of protein kinase CI activity improves metabolic dysfunction in human adipocytes from obese individuals

Robert Sparks, Ashley Lui, Deena Bader, Rekha Patel, Michel Murr, Wayne Guida, Rutilio Fratti, Niketa A. Patel

Research output: Contribution to journalArticle

Abstract

The metabolic consequences and sequelae of obesity promote life-threatening morbidities. PKCI is an important elicitor of inflammation and apoptosis in adipocytes. Here we report increased PKCI activation via release of its catalytic domain concurrent with increased expression of proinflammatory cytokines in adipocytes from obese individuals. Using a screening strategy of dual recognition of PKCI isozymes and a caspase-3 binding site on the PKCI hinge domain with Schrödinger software and molecular dynamics simulations, we identified NP627, an organic small-molecule inhibitor of PKCI. Characterization of NP627 by surface plasmon resonance (SPR) revealed that PKCI and NP627 interact with each other with high affinity and specificity, SPR kinetics revealed that NP627 disrupts caspase-3 binding to PKCI, and in vitro kinase assays demonstrated that NP627 specifically inhibits PKCI activity. The SPR results also indicated that NP627 affects macromolecular interactions between protein surfaces. Of note, release of the PKCI catalytic fragment was sufficient to induce apoptosis and inflammation in adipocytes. NP627 treatment of adipocytes from obese individuals significantly inhibited PKCI catalytic fragment release, decreased inflammation and apoptosis, and significantly improved mitochondrial metabolism. These results indicate that PKCI is a robust candidate for targeted interventions to manage obesity-associated chronic inflammatory diseases. We propose that NP627 may also be used in other biological systems to better understand the impact of caspase-3-mediated activation of kinase activity.

Original languageEnglish (US)
Pages (from-to)14896-14910
Number of pages15
JournalJournal of Biological Chemistry
Volume294
Issue number41
DOIs
StatePublished - Jan 1 2019

Fingerprint

Surface plasmon resonance
Protein Kinase Inhibitors
Adipocytes
Caspase 3
Surface Plasmon Resonance
Apoptosis
Molecules
Phosphotransferases
Inflammation
Chemical activation
Obesity
Biological systems
Hinges
Metabolism
Isoenzymes
Molecular dynamics
Assays
Screening
Membrane Proteins
Molecular Dynamics Simulation

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

A specific small-molecule inhibitor of protein kinase CI activity improves metabolic dysfunction in human adipocytes from obese individuals. / Sparks, Robert; Lui, Ashley; Bader, Deena; Patel, Rekha; Murr, Michel; Guida, Wayne; Fratti, Rutilio; Patel, Niketa A.

In: Journal of Biological Chemistry, Vol. 294, No. 41, 01.01.2019, p. 14896-14910.

Research output: Contribution to journalArticle

Sparks, Robert ; Lui, Ashley ; Bader, Deena ; Patel, Rekha ; Murr, Michel ; Guida, Wayne ; Fratti, Rutilio ; Patel, Niketa A. / A specific small-molecule inhibitor of protein kinase CI activity improves metabolic dysfunction in human adipocytes from obese individuals. In: Journal of Biological Chemistry. 2019 ; Vol. 294, No. 41. pp. 14896-14910.
@article{defca017b224407d9a7ad9dfb16038ba,
title = "A specific small-molecule inhibitor of protein kinase CI activity improves metabolic dysfunction in human adipocytes from obese individuals",
abstract = "The metabolic consequences and sequelae of obesity promote life-threatening morbidities. PKCI is an important elicitor of inflammation and apoptosis in adipocytes. Here we report increased PKCI activation via release of its catalytic domain concurrent with increased expression of proinflammatory cytokines in adipocytes from obese individuals. Using a screening strategy of dual recognition of PKCI isozymes and a caspase-3 binding site on the PKCI hinge domain with Schr{\"o}dinger software and molecular dynamics simulations, we identified NP627, an organic small-molecule inhibitor of PKCI. Characterization of NP627 by surface plasmon resonance (SPR) revealed that PKCI and NP627 interact with each other with high affinity and specificity, SPR kinetics revealed that NP627 disrupts caspase-3 binding to PKCI, and in vitro kinase assays demonstrated that NP627 specifically inhibits PKCI activity. The SPR results also indicated that NP627 affects macromolecular interactions between protein surfaces. Of note, release of the PKCI catalytic fragment was sufficient to induce apoptosis and inflammation in adipocytes. NP627 treatment of adipocytes from obese individuals significantly inhibited PKCI catalytic fragment release, decreased inflammation and apoptosis, and significantly improved mitochondrial metabolism. These results indicate that PKCI is a robust candidate for targeted interventions to manage obesity-associated chronic inflammatory diseases. We propose that NP627 may also be used in other biological systems to better understand the impact of caspase-3-mediated activation of kinase activity.",
author = "Robert Sparks and Ashley Lui and Deena Bader and Rekha Patel and Michel Murr and Wayne Guida and Rutilio Fratti and Patel, {Niketa A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1074/jbc.RA119.008777",
language = "English (US)",
volume = "294",
pages = "14896--14910",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "41",

}

TY - JOUR

T1 - A specific small-molecule inhibitor of protein kinase CI activity improves metabolic dysfunction in human adipocytes from obese individuals

AU - Sparks, Robert

AU - Lui, Ashley

AU - Bader, Deena

AU - Patel, Rekha

AU - Murr, Michel

AU - Guida, Wayne

AU - Fratti, Rutilio

AU - Patel, Niketa A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The metabolic consequences and sequelae of obesity promote life-threatening morbidities. PKCI is an important elicitor of inflammation and apoptosis in adipocytes. Here we report increased PKCI activation via release of its catalytic domain concurrent with increased expression of proinflammatory cytokines in adipocytes from obese individuals. Using a screening strategy of dual recognition of PKCI isozymes and a caspase-3 binding site on the PKCI hinge domain with Schrödinger software and molecular dynamics simulations, we identified NP627, an organic small-molecule inhibitor of PKCI. Characterization of NP627 by surface plasmon resonance (SPR) revealed that PKCI and NP627 interact with each other with high affinity and specificity, SPR kinetics revealed that NP627 disrupts caspase-3 binding to PKCI, and in vitro kinase assays demonstrated that NP627 specifically inhibits PKCI activity. The SPR results also indicated that NP627 affects macromolecular interactions between protein surfaces. Of note, release of the PKCI catalytic fragment was sufficient to induce apoptosis and inflammation in adipocytes. NP627 treatment of adipocytes from obese individuals significantly inhibited PKCI catalytic fragment release, decreased inflammation and apoptosis, and significantly improved mitochondrial metabolism. These results indicate that PKCI is a robust candidate for targeted interventions to manage obesity-associated chronic inflammatory diseases. We propose that NP627 may also be used in other biological systems to better understand the impact of caspase-3-mediated activation of kinase activity.

AB - The metabolic consequences and sequelae of obesity promote life-threatening morbidities. PKCI is an important elicitor of inflammation and apoptosis in adipocytes. Here we report increased PKCI activation via release of its catalytic domain concurrent with increased expression of proinflammatory cytokines in adipocytes from obese individuals. Using a screening strategy of dual recognition of PKCI isozymes and a caspase-3 binding site on the PKCI hinge domain with Schrödinger software and molecular dynamics simulations, we identified NP627, an organic small-molecule inhibitor of PKCI. Characterization of NP627 by surface plasmon resonance (SPR) revealed that PKCI and NP627 interact with each other with high affinity and specificity, SPR kinetics revealed that NP627 disrupts caspase-3 binding to PKCI, and in vitro kinase assays demonstrated that NP627 specifically inhibits PKCI activity. The SPR results also indicated that NP627 affects macromolecular interactions between protein surfaces. Of note, release of the PKCI catalytic fragment was sufficient to induce apoptosis and inflammation in adipocytes. NP627 treatment of adipocytes from obese individuals significantly inhibited PKCI catalytic fragment release, decreased inflammation and apoptosis, and significantly improved mitochondrial metabolism. These results indicate that PKCI is a robust candidate for targeted interventions to manage obesity-associated chronic inflammatory diseases. We propose that NP627 may also be used in other biological systems to better understand the impact of caspase-3-mediated activation of kinase activity.

UR - http://www.scopus.com/inward/record.url?scp=85073183031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073183031&partnerID=8YFLogxK

U2 - 10.1074/jbc.RA119.008777

DO - 10.1074/jbc.RA119.008777

M3 - Article

C2 - 31413114

AN - SCOPUS:85073183031

VL - 294

SP - 14896

EP - 14910

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 41

ER -